Notice of Effectiveness · EFFECT
MAIA Biotechnology, Inc.
MAIANYSE_AMERICANEQUITYCurrent
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-10-06
- Effective time (as filed)
- 17:00:00
- Form
- S-3
Registrant 1
- Registrant
- MAIA Biotechnology, Inc.
- Registrant CIK
- 0001878313
- File number
- 333-299148
Company context
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.